Fundraising Fox
Unum Therapeutics
NASDAQ: COGTCambridge, US · Founded 2014 · Delaware corporation · 315 employees on LinkedIn · 3 known investors
Find your way into Unum Therapeutics
Sign up to see every warm intro you have to Unum Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Unum Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cogent Biosciences is a biotechnology company developing small molecule precision therapies for genetically driven diseases where the cause is linked to a specific genetic mutation. It runs a discovery organization in Boulder, Colorado, aiming to create treatments for patients with unmet medical needs.
Founders & leadership
Unum Therapeutics was founded in 2014 by Charles Wilson.
CW
Charles WilsonFounder
CS
Christiana StamoulisExecutiveChristiana Stamoulis held executive finance and strategy roles at Incyte (EVP and CFO, 2019–2025), Unum Therapeutics (CFO and President), and Vertex Pharmaceuticals (SVP of Corporate Strategy and Business Development), where she contributed to Vertex's strategic shift to cystic fibrosis. She previously spent 15 years in investment banking and consulting at Citigroup, Goldman Sachs, and Boston Consulting Group.
Board
BA
Ben AuspitzBoard director
LR
Liam RatcliffeBoard director
BB
Investors · 3
Reported raises · per SEC filings
Form D private placements$220.5M disclosed across 4 rounds · 2014–2020
▶$44.8MraisedJul 2020 · 2 investors · BiotechnologyRule 506(b)
▶$44.8MraisedJul 2020 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles WilsonExecutive Officer, Director
- Arlene MorrisDirector
- Jessica SachsExecutive Officer
- Karen FerranteDirector
- John L. GreenExecutive Officer
- Matthew RosDirector
- Chris CainDirector
- Peter HarwinDirector
- Offering amount
- $44.8M
- Amount sold
- $44.8M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$104.4MraisedJul 2020 · 22 investors · BiotechnologyRule 506(b)
▶$104.4MraisedJul 2020 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew RosDirector
- John L. GreenExecutive Officer
- Arlene MorrisDirector
- Jessica SachsExecutive Officer
- Chris CainDirector
- Karen FerranteDirector
- Charles WilsonExecutive Officer, Director
- Peter HarwinDirector
- Offering amount
- $104.4M
- Amount sold
- $104.4M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$65MraisedJun 2015 · 13 investors · BiotechnologyRule 506(b)
▶$65MraisedJun 2015 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ben AuspitzDirector
- Liam RatcliffeDirector
- Charles WilsonExecutive Officer, Director
- Christiana StamoulisExecutive Officer
- Bruce BoothDirector
- Offering amount
- $65M
- Amount sold
- $65M
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$6.3MraisedOct 2014 · 3 investors · Other Health CareRule 506(b)
▶$6.3MraisedOct 2014 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Bruce BoothDirector
- Ben AuspitzDirector
- Charles WilsonExecutive Officer, Director
- Offering amount
- $12.3M
- Amount sold
- $6.3M
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$355.4Mvaluation at IPOMar 2018 · $12.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 3
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Unum Therapeutics.
Frequently asked questions
- What does Unum Therapeutics do?
- Cogent Biosciences is a biotechnology company developing small molecule precision therapies for genetically driven diseases where the cause is linked to a specific genetic mutation. It runs a discovery organization in Boulder, Colorado, aiming to create treatments for patients with unmet medical needs.
- Who founded Unum Therapeutics?
- Unum Therapeutics was founded by Charles Wilson in 2014.
- Who are Unum Therapeutics's investors?
- Unum Therapeutics's investors include Atlas Venture, F-Prime Capital, Sanofi Ventures.
- How much funding has Unum Therapeutics raised?
- Unum Therapeutics has disclosed $220.5M raised across 4 rounds.
- Where is Unum Therapeutics headquartered?
- Unum Therapeutics is headquartered in Cambridge, US.